Related Experiment Video
Updated: Aug 7, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
Drug evaluation: STA-4783--enhancing taxane efficacy by induction of Hsp70
1University Hospital Regensburg, Dept. Hematology/Oncology, Molecular Oncology, H1 Carreras FoBau Franz-Josef-Strauss-Allee 11, D-93053 Regensburg, Germany. mathias.gehrmann@klinik.uni-regensburg.de
Abstract:
The apoptosis stimulator STA-4783 acts by inducing expression of heat shock protein (Hsp)70 on tumor cell surfaces and disrupting the cytoskeletal network. Currently in development by Synta Pharmaceuticals for the potential treatment of solid tumors, phase II clinical trials in non-small-cell lung cancer, melanoma and sarcoma have been initiated.
Insights
The apoptosis stimulator STA-4783 enhances tumor cell surface heat shock protein 70 (Hsp70) expression and disrupts cellular structure. Synta Pharmaceuticals is investigating STA-4783 for solid tumor treatment in ongoing clinical trials.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Solid tumors present significant therapeutic challenges.
- Targeting tumor cell surface proteins and cytoskeletal integrity is a key strategy in cancer therapy.
- Heat shock proteins (Hsps) play crucial roles in cellular stress response and survival.
Purpose of the Study:
- To investigate the mechanism of action of the apoptosis stimulator STA-4783.
- To evaluate the potential of STA-4783 as a novel therapeutic agent for solid tumors.
Main Methods:
- STA-4783 treatment of tumor cells.
- Analysis of heat shock protein 70 (Hsp70) expression on tumor cell surfaces.
- Assessment of cytoskeletal network integrity.
Main Results:
- STA-4783 induces expression of Hsp70 on the surface of tumor cells.
- STA-4783 disrupts the cytoskeletal network within tumor cells.
Conclusions:
- STA-4783 exhibits a dual mechanism of action involving Hsp70 induction and cytoskeletal disruption.
- STA-4783 shows promise as a potential treatment for solid tumors, warranting further clinical investigation.
Related Concept Videos
Drugs that Stabilize Microtubules
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Drugs that Destabilize Microtubules

